CZ166797A3 - Application of metal complexes as liver and gallbladder x-ray diagnostic agents - Google Patents

Application of metal complexes as liver and gallbladder x-ray diagnostic agents Download PDF

Info

Publication number: CZ166797A3
Authority: CZ; Czechia
Prior art keywords: acid; triaza; carboxymethyl; tris; complex
Prior art date: 1994-11-30

Application number

CZ971667A

Other languages

Czech (cs)

English (en)

Inventor

Franz-Karl Maier

Michael Bauer

Werner Krause

Urlich Speck

Gabriele Schuhmann-Giampieri

Andreas Muhler

Thomas Balzer

Wolf-Rudiger Press

Original Assignee

Schering Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-11-30

Filing date

1995-11-20

Publication date

1997-11-12

1995-11-20 Application filed by Schering Ag filed Critical Schering Ag

1995-11-20 Priority claimed from PCT/DE1995/001644 external-priority patent/WO1996016677A2/fr

1997-11-12 Publication of CZ166797A3 publication Critical patent/CZ166797A3/cs

Links

210000004185 liver Anatomy 0.000 title claims abstract description 40
229910052751 metal Inorganic materials 0.000 title claims abstract description 20
239000002184 metal Substances 0.000 title claims abstract description 20
210000000232 gallbladder Anatomy 0.000 title description 4
229940039227 diagnostic agent Drugs 0.000 title 1
239000000032 diagnostic agent Substances 0.000 title 1
239000002872 contrast media Substances 0.000 claims abstract description 36
238000002591 computed tomography Methods 0.000 claims abstract description 29
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract description 3
239000002253 acid Substances 0.000 claims description 36
-1 hydrocarbon radical Chemical class 0.000 claims description 35
229910052739 hydrogen Inorganic materials 0.000 claims description 34
150000001875 compounds Chemical class 0.000 claims description 27
229910052769 Ytterbium Inorganic materials 0.000 claims description 14
239000013522 chelant Substances 0.000 claims description 12
NAWDYIZEMPQZHO-UHFFFAOYSA-N ytterbium Chemical compound [Yb] NAWDYIZEMPQZHO-UHFFFAOYSA-N 0.000 claims description 11
IFTSPPZCXMKCRQ-UHFFFAOYSA-N C(=O)(O)CN(CC(C(=O)O)C(=O)O)C(CN(CCN(CC)CC(=O)O)CC(=O)O)CC1=CC=C(C=C1)OCC Chemical compound C(=O)(O)CN(CC(C(=O)O)C(=O)O)C(CN(CCN(CC)CC(=O)O)CC(=O)O)CC1=CC=C(C=C1)OCC IFTSPPZCXMKCRQ-UHFFFAOYSA-N 0.000 claims description 9
150000003254 radicals Chemical class 0.000 claims description 9
OHSVLFRHMCKCQY-UHFFFAOYSA-N lutetium atom Chemical compound [Lu] OHSVLFRHMCKCQY-UHFFFAOYSA-N 0.000 claims description 8
229910021645 metal ion Inorganic materials 0.000 claims description 8
229910052688 Gadolinium Inorganic materials 0.000 claims description 7
150000001408 amides Chemical class 0.000 claims description 7
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 7
UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 claims description 6
239000001257 hydrogen Substances 0.000 claims description 6
239000007983 Tris buffer Substances 0.000 claims description 5
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 4
GGADBTALKKVKIA-UHFFFAOYSA-N C(=O)(O)CN(CC(C(=O)O)C(=O)O)C(CN(CC(N(CC)CC(=O)O)CC1=CC=C(C=C1)CCCC)CC(=O)O)CC1=CC=C(C=C1)CCCC Chemical compound C(=O)(O)CN(CC(C(=O)O)C(=O)O)C(CN(CC(N(CC)CC(=O)O)CC1=CC=C(C=C1)CCCC)CC(=O)O)CC1=CC=C(C=C1)CCCC GGADBTALKKVKIA-UHFFFAOYSA-N 0.000 claims description 4
SURRFDXJJDNZAQ-UHFFFAOYSA-N C(=O)(O)CN(CC(C(=O)O)C(=O)O)C(CN(CCN(CC)CC(=O)O)CC(=O)O)CC1=CC=C(C=C1)CCCC Chemical compound C(=O)(O)CN(CC(C(=O)O)C(=O)O)C(CN(CCN(CC)CC(=O)O)CC(=O)O)CC1=CC=C(C=C1)CCCC SURRFDXJJDNZAQ-UHFFFAOYSA-N 0.000 claims description 4
229910052692 Dysprosium Inorganic materials 0.000 claims description 4
229910052691 Erbium Inorganic materials 0.000 claims description 4
229910052689 Holmium Inorganic materials 0.000 claims description 4
229910052777 Praseodymium Inorganic materials 0.000 claims description 4
229910052797 bismuth Inorganic materials 0.000 claims description 4
JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 claims description 4
125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 4
150000001768 cations Chemical class 0.000 claims description 4
KBQHZAAAGSGFKK-UHFFFAOYSA-N dysprosium atom Chemical compound [Dy] KBQHZAAAGSGFKK-UHFFFAOYSA-N 0.000 claims description 4
UYAHIZSMUZPPFV-UHFFFAOYSA-N erbium Chemical compound [Er] UYAHIZSMUZPPFV-UHFFFAOYSA-N 0.000 claims description 4
229910052735 hafnium Inorganic materials 0.000 claims description 4
VBJZVLUMGGDVMO-UHFFFAOYSA-N hafnium atom Chemical compound [Hf] VBJZVLUMGGDVMO-UHFFFAOYSA-N 0.000 claims description 4
KJZYNXUDTRRSPN-UHFFFAOYSA-N holmium atom Chemical compound [Ho] KJZYNXUDTRRSPN-UHFFFAOYSA-N 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
PUDIUYLPXJFUGB-UHFFFAOYSA-N praseodymium atom Chemical compound [Pr] PUDIUYLPXJFUGB-UHFFFAOYSA-N 0.000 claims description 4
UEELOZZYJQSLLY-UHFFFAOYSA-N 5-[(4-ethoxyphenyl)methyl]dodecane-1,2,2-tricarboxylic acid Chemical compound CCCCCCCC(CCC(CC(O)=O)(C(O)=O)C(O)=O)CC1=CC=C(OCC)C=C1 UEELOZZYJQSLLY-UHFFFAOYSA-N 0.000 claims description 3
LMIBWBXZGSYHQS-UHFFFAOYSA-N C(=O)(O)CN(CC(C(=O)O)C(=O)O)C(CN(CCN(CC)CC(=O)O)CC(=O)O)CC1=C(C=CC=C1)OCC Chemical compound C(=O)(O)CN(CC(C(=O)O)C(=O)O)C(CN(CCN(CC)CC(=O)O)CC(=O)O)CC1=C(C=CC=C1)OCC LMIBWBXZGSYHQS-UHFFFAOYSA-N 0.000 claims description 3
229910052684 Cerium Inorganic materials 0.000 claims description 3
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims description 3
125000004432 carbon atom Chemical group C* 0.000 claims description 3
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
RJOJUSXNYCILHH-UHFFFAOYSA-N gadolinium(3+) Chemical compound [Gd+3] RJOJUSXNYCILHH-UHFFFAOYSA-N 0.000 claims description 3
150000002602 lanthanoids Chemical group 0.000 claims description 3
125000004430 oxygen atom Chemical group O* 0.000 claims description 3
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims description 2
SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical compound [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 claims description 2
239000004475 Arginine Substances 0.000 claims description 2
AQGMWDALCYXWQV-UHFFFAOYSA-N C(=O)(O)CC(CCC(CCCCCCC)CC1=CC=C(C=C1)CCCC)(C(=O)O)C(=O)O Chemical compound C(=O)(O)CC(CCC(CCCCCCC)CC1=CC=C(C=C1)CCCC)(C(=O)O)C(=O)O AQGMWDALCYXWQV-UHFFFAOYSA-N 0.000 claims description 2
GVCVXVLHLRQXBY-UHFFFAOYSA-N C(=O)(O)CN(CCC(=O)O)C(CN(CCN(CC)CC(=O)O)CC(=O)O)CC1=CC=C(C=C1)OCC Chemical compound C(=O)(O)CN(CCC(=O)O)C(CN(CCN(CC)CC(=O)O)CC(=O)O)CC1=CC=C(C=C1)OCC GVCVXVLHLRQXBY-UHFFFAOYSA-N 0.000 claims description 2
239000004215 Carbon black (E152) Substances 0.000 claims description 2
AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 2
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
239000004472 Lysine Substances 0.000 claims description 2
AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 2
UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 2
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
229960003121 arginine Drugs 0.000 claims description 2
125000003118 aryl group Chemical group 0.000 claims description 2
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 2
210000003445 biliary tract Anatomy 0.000 claims description 2
229960002442 glucosamine Drugs 0.000 claims description 2
229930195733 hydrocarbon Natural products 0.000 claims description 2
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
229960003646 lysine Drugs 0.000 claims description 2
229960003194 meglumine Drugs 0.000 claims description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
150000002892 organic cations Chemical class 0.000 claims description 2
229960003104 ornithine Drugs 0.000 claims description 2
WCWKKSOQLQEJTE-UHFFFAOYSA-N praseodymium(3+) Chemical compound [Pr+3] WCWKKSOQLQEJTE-UHFFFAOYSA-N 0.000 claims 2
JDIBGQFKXXXXPN-UHFFFAOYSA-N bismuth(3+) Chemical compound [Bi+3] JDIBGQFKXXXXPN-UHFFFAOYSA-N 0.000 claims 1
ZMIGMASIKSOYAM-UHFFFAOYSA-N cerium Chemical compound [Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce] ZMIGMASIKSOYAM-UHFFFAOYSA-N 0.000 claims 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
AWSFICBXMUKWSK-UHFFFAOYSA-N ytterbium(3+) Chemical compound [Yb+3] AWSFICBXMUKWSK-UHFFFAOYSA-N 0.000 claims 1
210000000013 bile duct Anatomy 0.000 abstract description 3
229940039231 contrast media Drugs 0.000 abstract description 3
QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical group OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 abstract 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 40
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
239000000126 substance Substances 0.000 description 32
229910052757 nitrogen Inorganic materials 0.000 description 31
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
229910052799 carbon Inorganic materials 0.000 description 25
238000004458 analytical method Methods 0.000 description 23
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
150000003839 salts Chemical class 0.000 description 17
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
238000003756 stirring Methods 0.000 description 13
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 12
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
SLYTULCOCGSBBJ-FCQHKQNSSA-I disodium;2-[[(2s)-2-[bis(carboxylatomethyl)amino]-3-(4-ethoxyphenyl)propyl]-[2-[bis(carboxylatomethyl)amino]ethyl]amino]acetate;gadolinium(3+) Chemical compound [Na+].[Na+].[Gd+3].CCOC1=CC=C(C[C@@H](CN(CCN(CC([O-])=O)CC([O-])=O)CC([O-])=O)N(CC([O-])=O)CC([O-])=O)C=C1 SLYTULCOCGSBBJ-FCQHKQNSSA-I 0.000 description 12
238000001802 infusion Methods 0.000 description 12
238000000034 method Methods 0.000 description 12
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 11
239000000706 filtrate Substances 0.000 description 11
229910052760 oxygen Inorganic materials 0.000 description 11
239000012074 organic phase Substances 0.000 description 10
239000000243 solution Substances 0.000 description 10
206010027476 Metastases Diseases 0.000 description 9
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
229910052740 iodine Inorganic materials 0.000 description 9
239000011630 iodine Substances 0.000 description 9
239000000047 product Substances 0.000 description 9
239000000741 silica gel Substances 0.000 description 9
229910002027 silica gel Inorganic materials 0.000 description 9
QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 8
241001465754 Metazoa Species 0.000 description 8
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 8
239000012230 colorless oil Substances 0.000 description 8
238000002474 experimental method Methods 0.000 description 8
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
239000011734 sodium Substances 0.000 description 8
229910052708 sodium Inorganic materials 0.000 description 8
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 8
238000001990 intravenous administration Methods 0.000 description 7
229910052938 sodium sulfate Inorganic materials 0.000 description 7
235000011152 sodium sulphate Nutrition 0.000 description 7
239000007787 solid Substances 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
150000002500 ions Chemical class 0.000 description 6
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
230000000694 effects Effects 0.000 description 5
239000000839 emulsion Substances 0.000 description 5
238000003384 imaging method Methods 0.000 description 5
230000003902 lesion Effects 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
239000011541 reaction mixture Substances 0.000 description 5
238000003325 tomography Methods 0.000 description 5
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
241000282412 Homo Species 0.000 description 4
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
206010027457 Metastases to liver Diseases 0.000 description 4
BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
238000010668 complexation reaction Methods 0.000 description 4
239000008139 complexing agent Substances 0.000 description 4
238000003745 diagnosis Methods 0.000 description 4
238000004108 freeze drying Methods 0.000 description 4
208000014018 liver neoplasm Diseases 0.000 description 4
238000005259 measurement Methods 0.000 description 4
239000003921 oil Substances 0.000 description 4
229910000027 potassium carbonate Inorganic materials 0.000 description 4
239000000725 suspension Substances 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
PMLGQXIKBPFHJZ-UHFFFAOYSA-N 3-aminobutane-1,2,4-triol Chemical compound OCC(N)C(O)CO PMLGQXIKBPFHJZ-UHFFFAOYSA-N 0.000 description 3
ADQZHEPAEBBNQJ-UHFFFAOYSA-N C(=O)(O)CN(CC(C(=O)O)C(=O)O)C(CN(CCN(CC)CC(=O)O)CC(=O)O)CC1=C(C=CC=C1)OCCCC Chemical compound C(=O)(O)CN(CC(C(=O)O)C(=O)O)C(CN(CCN(CC)CC(=O)O)CC(=O)O)CC1=C(C=CC=C1)OCCCC ADQZHEPAEBBNQJ-UHFFFAOYSA-N 0.000 description 3
206010019695 Hepatic neoplasm Diseases 0.000 description 3
206010028980 Neoplasm Diseases 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
238000010521 absorption reaction Methods 0.000 description 3
239000003610 charcoal Substances 0.000 description 3
238000001704 evaporation Methods 0.000 description 3
230000008020 evaporation Effects 0.000 description 3
238000001914 filtration Methods 0.000 description 3
210000005228 liver tissue Anatomy 0.000 description 3
JCDQGOSXWGXOQQ-UHFFFAOYSA-H ytterbium(3+);tricarbonate Chemical compound [Yb+3].[Yb+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O JCDQGOSXWGXOQQ-UHFFFAOYSA-H 0.000 description 3
AQOXEJNYXXLRQQ-UHFFFAOYSA-N 2-[[2-[bis(carboxymethyl)amino]-3-(4-ethoxyphenyl)propyl]-[2-[bis(carboxymethyl)amino]ethyl]amino]acetic acid Chemical compound CCOC1=CC=C(CC(CN(CCN(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 AQOXEJNYXXLRQQ-UHFFFAOYSA-N 0.000 description 2
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
JWMHUPYAUKBORY-UHFFFAOYSA-N CCN(CCN(CC(=O)O)C(CC1=CC=C(C=C1)OCCOCCOCC)CN(CC(C(=O)O)C(=O)O)CC(=O)O)CC(=O)O Chemical compound CCN(CCN(CC(=O)O)C(CC1=CC=C(C=C1)OCCOCCOCC)CN(CC(C(=O)O)C(=O)O)CC(=O)O)CC(=O)O JWMHUPYAUKBORY-UHFFFAOYSA-N 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
238000009825 accumulation Methods 0.000 description 2
125000000217 alkyl group Chemical group 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
229910021529 ammonia Inorganic materials 0.000 description 2
235000011114 ammonium hydroxide Nutrition 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
229910052786 argon Inorganic materials 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
230000037396 body weight Effects 0.000 description 2
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
239000003054 catalyst Substances 0.000 description 2
GWXLDORMOJMVQZ-UHFFFAOYSA-N cerium Chemical compound [Ce] GWXLDORMOJMVQZ-UHFFFAOYSA-N 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
150000004696 coordination complex Chemical class 0.000 description 2
239000002274 desiccant Substances 0.000 description 2
230000004069 differentiation Effects 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
239000003480 eluent Substances 0.000 description 2
230000002708 enhancing effect Effects 0.000 description 2
230000007717 exclusion Effects 0.000 description 2
230000002440 hepatic effect Effects 0.000 description 2
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
238000004255 ion exchange chromatography Methods 0.000 description 2
229910052747 lanthanoid Inorganic materials 0.000 description 2
239000002502 liposome Substances 0.000 description 2
230000033001 locomotion Effects 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
229910052749 magnesium Inorganic materials 0.000 description 2
QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
RBDUQCYSANZYNZ-KRWDZBQOSA-N methyl (2s)-3-(2-ethoxyphenyl)-2-(phenylmethoxycarbonylamino)propanoate Chemical compound CCOC1=CC=CC=C1C[C@@H](C(=O)OC)NC(=O)OCC1=CC=CC=C1 RBDUQCYSANZYNZ-KRWDZBQOSA-N 0.000 description 2
239000002480 mineral oil Substances 0.000 description 2
235000010446 mineral oil Nutrition 0.000 description 2
229910052763 palladium Inorganic materials 0.000 description 2
230000010412 perfusion Effects 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
238000002953 preparative HPLC Methods 0.000 description 2
238000000746 purification Methods 0.000 description 2
238000011160 research Methods 0.000 description 2
239000012279 sodium borohydride Substances 0.000 description 2
229910000033 sodium borohydride Inorganic materials 0.000 description 2
239000012312 sodium hydride Substances 0.000 description 2
229910000104 sodium hydride Inorganic materials 0.000 description 2
241000894007 species Species 0.000 description 2
BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 2
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
ZCUFMDLYAMJYST-UHFFFAOYSA-N thorium dioxide Chemical compound O=[Th]=O ZCUFMDLYAMJYST-UHFFFAOYSA-N 0.000 description 2
238000002604 ultrasonography Methods 0.000 description 2
229910052725 zinc Inorganic materials 0.000 description 2
239000011701 zinc Substances 0.000 description 2
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
MFEVGQHCNVXMER-UHFFFAOYSA-L 1,3,2$l^{2}-dioxaplumbetan-4-one Chemical compound [Pb+2].[O-]C([O-])=O MFEVGQHCNVXMER-UHFFFAOYSA-L 0.000 description 1
UEDIWIFQWRXXJG-UHFFFAOYSA-N 1-(2-bromoethoxy)-2-ethoxyethane Chemical compound CCOCCOCCBr UEDIWIFQWRXXJG-UHFFFAOYSA-N 0.000 description 1
MPPPKRYCTPRNTB-UHFFFAOYSA-N 1-bromobutane Chemical compound CCCCBr MPPPKRYCTPRNTB-UHFFFAOYSA-N 0.000 description 1
LNBUPUZCHNMUGR-UHFFFAOYSA-N 2-[2-[[1-[bis(carboxymethyl)amino]-3-(4-ethoxyphenyl)propan-2-yl]-(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound CCOC1=CC=C(CC(CN(CC(O)=O)CC(O)=O)N(CCN(CC(O)=O)CC(O)=O)CC(O)=O)C=C1 LNBUPUZCHNMUGR-UHFFFAOYSA-N 0.000 description 1
WRFPVMFCRNYQNR-UHFFFAOYSA-N 2-hydroxyphenylalanine Chemical compound OC(=O)C(N)CC1=CC=CC=C1O WRFPVMFCRNYQNR-UHFFFAOYSA-N 0.000 description 1
102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
108010082126 Alanine transaminase Proteins 0.000 description 1
108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
229910000014 Bismuth subcarbonate Inorganic materials 0.000 description 1
ZUTRLLMFKYYXTJ-UHFFFAOYSA-N C(=O)(O)CC(CCC(CCCC(CCC)CC1=CC=C(C=C1)CCCC)CC1=CC=C(C=C1)CCCC)(C(=O)O)C(=O)O Chemical compound C(=O)(O)CC(CCC(CCCC(CCC)CC1=CC=C(C=C1)CCCC)CC1=CC=C(C=C1)CCCC)(C(=O)O)C(=O)O ZUTRLLMFKYYXTJ-UHFFFAOYSA-N 0.000 description 1
VJHBCQVRWMBRDE-UHFFFAOYSA-N C(=O)(O)CC(CCC(CCCCCCC)CC1=C(C=CC=C1)OCC)(C(=O)O)C(=O)O Chemical compound C(=O)(O)CC(CCC(CCCCCCC)CC1=C(C=CC=C1)OCC)(C(=O)O)C(=O)O VJHBCQVRWMBRDE-UHFFFAOYSA-N 0.000 description 1
RSJVCWIPNXKBRP-UHFFFAOYSA-N C(C)(C)(C)OC(=O)C(CN(CC(N(CCN(CC)CC(=O)OC(C)(C)C)CC(=O)OC(C)(C)C)CC1=CC=C(C=C1)OCCOCCOCC)CC(=O)OC(C)(C)C)C(=O)OC(C)(C)C Chemical compound C(C)(C)(C)OC(=O)C(CN(CC(N(CCN(CC)CC(=O)OC(C)(C)C)CC(=O)OC(C)(C)C)CC1=CC=C(C=C1)OCCOCCOCC)CC(=O)OC(C)(C)C)C(=O)OC(C)(C)C RSJVCWIPNXKBRP-UHFFFAOYSA-N 0.000 description 1
HHIOPIDJGPOXKR-SFHVURJKSA-N C(C1=CC=CC=C1)OC(=O)N[C@@H](CC1=C(C=CC=C1)OCCCC)C(=O)O Chemical compound C(C1=CC=CC=C1)OC(=O)N[C@@H](CC1=C(C=CC=C1)OCCCC)C(=O)O HHIOPIDJGPOXKR-SFHVURJKSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
FXPWEXKNUKRIAG-UHFFFAOYSA-N Cl.Cl.C(C)OC1=C(CC(N)CNCCN)C=CC=C1 Chemical compound Cl.Cl.C(C)OC1=C(CC(N)CNCCN)C=CC=C1 FXPWEXKNUKRIAG-UHFFFAOYSA-N 0.000 description 1
RVLIAMATLKEMBY-UHFFFAOYSA-N Cl.Cl.C(CCC)OC1=C(CC(N)CNCCN)C=CC=C1 Chemical compound Cl.Cl.C(CCC)OC1=C(CC(N)CNCCN)C=CC=C1 RVLIAMATLKEMBY-UHFFFAOYSA-N 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
208000001333 Colorectal Neoplasms Diseases 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
229910017569 La2(CO3)3 Inorganic materials 0.000 description 1
229910000003 Lead carbonate Inorganic materials 0.000 description 1
208000018142 Leiomyosarcoma Diseases 0.000 description 1
229910052765 Lutetium Inorganic materials 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
QYEDKINEZPFKAE-VVTWOHJOSA-N N(C)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.N(C)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.N(C)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.[Ca+2] Chemical compound N(C)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.N(C)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.N(C)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.[Ca+2] QYEDKINEZPFKAE-VVTWOHJOSA-N 0.000 description 1
CMSHUVDQRFSNMH-IVKNCBPUSA-N N(C)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.N(C)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.[Ho+3] Chemical compound N(C)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.N(C)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.[Ho+3] CMSHUVDQRFSNMH-IVKNCBPUSA-N 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
208000005718 Stomach Neoplasms Diseases 0.000 description 1
229910052771 Terbium Inorganic materials 0.000 description 1
229910052776 Thorium Inorganic materials 0.000 description 1
229910052775 Thulium Inorganic materials 0.000 description 1
241000192325 [Candida] mesenterica Species 0.000 description 1
DGUBPXVBOHLLBL-UHFFFAOYSA-N [Gd].[Na].[Na] Chemical compound [Gd].[Na].[Na] DGUBPXVBOHLLBL-UHFFFAOYSA-N 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
229940009098 aspartate Drugs 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
239000002585 base Substances 0.000 description 1
HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
URICAEJNLJCPMR-UHFFFAOYSA-N benzyl n-[1-(2-butoxyphenyl)-3-hydroxypropan-2-yl]carbamate Chemical compound CCCCOC1=CC=CC=C1CC(CO)NC(=O)OCC1=CC=CC=C1 URICAEJNLJCPMR-UHFFFAOYSA-N 0.000 description 1
HFVRZFJGABRTRL-UHFFFAOYSA-N benzyl n-[1-(2-ethoxyphenyl)-3-hydroxypropan-2-yl]carbamate Chemical compound CCOC1=CC=CC=C1CC(CO)NC(=O)OCC1=CC=CC=C1 HFVRZFJGABRTRL-UHFFFAOYSA-N 0.000 description 1
KQWAYNHXBQBMPK-UHFFFAOYSA-N benzyl n-[2-[[2-amino-3-(2-ethoxyphenyl)propyl]amino]ethyl]carbamate Chemical compound CCOC1=CC=CC=C1CC(N)CNCCNC(=O)OCC1=CC=CC=C1 KQWAYNHXBQBMPK-UHFFFAOYSA-N 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
208000002458 carcinoid tumor Diseases 0.000 description 1
239000003729 cation exchange resin Substances 0.000 description 1
GHLITDDQOMIBFS-UHFFFAOYSA-H cerium(3+);tricarbonate Chemical compound [Ce+3].[Ce+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O GHLITDDQOMIBFS-UHFFFAOYSA-H 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000000536 complexating effect Effects 0.000 description 1
238000002247 constant time method Methods 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000000326 densiometry Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
FWIZHMQARNODNX-UHFFFAOYSA-L dibismuth;oxygen(2-);carbonate Chemical compound [O-2].[O-2].[Bi+3].[Bi+3].[O-]C([O-])=O FWIZHMQARNODNX-UHFFFAOYSA-L 0.000 description 1
DENRZWYUOJLTMF-UHFFFAOYSA-N diethyl sulfate Chemical compound CCOS(=O)(=O)OCC DENRZWYUOJLTMF-UHFFFAOYSA-N 0.000 description 1
229940008406 diethyl sulfate Drugs 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
238000009826 distribution Methods 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
229910003440 dysprosium oxide Inorganic materials 0.000 description 1
NLQFUUYNQFMIJW-UHFFFAOYSA-N dysprosium(iii) oxide Chemical compound O=[Dy]O[Dy]=O NLQFUUYNQFMIJW-UHFFFAOYSA-N 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
ZXGIFJXRQHZCGJ-UHFFFAOYSA-N erbium(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Er+3].[Er+3] ZXGIFJXRQHZCGJ-UHFFFAOYSA-N 0.000 description 1
VQCBHWLJZDBHOS-UHFFFAOYSA-N erbium(III) oxide Inorganic materials O=[Er]O[Er]=O VQCBHWLJZDBHOS-UHFFFAOYSA-N 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000029142 excretion Effects 0.000 description 1
210000001723 extracellular space Anatomy 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
229910001938 gadolinium oxide Inorganic materials 0.000 description 1
229940075613 gadolinium oxide Drugs 0.000 description 1
CMIHHWBVHJVIGI-UHFFFAOYSA-N gadolinium(iii) oxide Chemical compound [O-2].[O-2].[O-2].[Gd+3].[Gd+3] CMIHHWBVHJVIGI-UHFFFAOYSA-N 0.000 description 1
IZOOGPBRAOKZFK-UHFFFAOYSA-K gadopentetate Chemical compound [Gd+3].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O IZOOGPBRAOKZFK-UHFFFAOYSA-K 0.000 description 1
LGMLJQFQKXPRGA-VPVMAENOSA-K gadopentetate dimeglumine Chemical compound [Gd+3].CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O LGMLJQFQKXPRGA-VPVMAENOSA-K 0.000 description 1
206010017758 gastric cancer Diseases 0.000 description 1
DFIPXJGORSQQQD-UHFFFAOYSA-N hafnium;tetrahydrate Chemical compound O.O.O.O.[Hf] DFIPXJGORSQQQD-UHFFFAOYSA-N 0.000 description 1
229910001385 heavy metal Inorganic materials 0.000 description 1
FZKKGPOEHOOXQE-UHFFFAOYSA-H holmium(3+);tricarbonate Chemical compound [Ho+3].[Ho+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O FZKKGPOEHOOXQE-UHFFFAOYSA-H 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
230000009545 invasion Effects 0.000 description 1
229940116559 iodinated x-ray contrast media Drugs 0.000 description 1
229960004647 iopamidol Drugs 0.000 description 1
XQZXYNRDCRIARQ-LURJTMIESA-N iopamidol Chemical compound C[C@H](O)C(=O)NC1=C(I)C(C(=O)NC(CO)CO)=C(I)C(C(=O)NC(CO)CO)=C1I XQZXYNRDCRIARQ-LURJTMIESA-N 0.000 description 1
229910052746 lanthanum Inorganic materials 0.000 description 1
FZLIPJUXYLNCLC-UHFFFAOYSA-N lanthanum atom Chemical compound [La] FZLIPJUXYLNCLC-UHFFFAOYSA-N 0.000 description 1
NZPIUJUFIFZSPW-UHFFFAOYSA-H lanthanum carbonate Chemical compound [La+3].[La+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O NZPIUJUFIFZSPW-UHFFFAOYSA-H 0.000 description 1
229960001633 lanthanum carbonate Drugs 0.000 description 1
210000005162 left hepatic lobe Anatomy 0.000 description 1
239000003446 ligand Substances 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
NWFSXLPYEJFOIW-IBGZPJMESA-N methyl (2s)-3-(2-butoxyphenyl)-2-(phenylmethoxycarbonylamino)propanoate Chemical compound CCCCOC1=CC=CC=C1C[C@@H](C(=O)OC)NC(=O)OCC1=CC=CC=C1 NWFSXLPYEJFOIW-IBGZPJMESA-N 0.000 description 1
KQWFIKSWAKRREI-HNNXBMFYSA-N methyl (2s)-3-(2-hydroxyphenyl)-2-(phenylmethoxycarbonylamino)propanoate Chemical compound C([C@@H](C(=O)OC)NC(=O)OCC=1C=CC=CC=1)C1=CC=CC=C1O KQWFIKSWAKRREI-HNNXBMFYSA-N 0.000 description 1
150000004702 methyl esters Chemical class 0.000 description 1
239000000203 mixture Substances 0.000 description 1
ZMPMYPQIIMYNGA-UHFFFAOYSA-N n'-(2-aminoethyl)ethane-1,2-diamine;dihydrochloride Chemical compound Cl.Cl.NCCNCCN ZMPMYPQIIMYNGA-UHFFFAOYSA-N 0.000 description 1
230000008693 nausea Effects 0.000 description 1
125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
WTWWXOGTJWMJHI-UHFFFAOYSA-N perflubron Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br WTWWXOGTJWMJHI-UHFFFAOYSA-N 0.000 description 1
229960001217 perflubron Drugs 0.000 description 1
230000008855 peristalsis Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
XIRHLBQGEYXJKG-UHFFFAOYSA-H praseodymium(3+);tricarbonate Chemical compound [Pr+3].[Pr+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O XIRHLBQGEYXJKG-UHFFFAOYSA-H 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
230000005855 radiation Effects 0.000 description 1
239000012217 radiopharmaceutical Substances 0.000 description 1
229940121896 radiopharmaceutical Drugs 0.000 description 1
230000002799 radiopharmaceutical effect Effects 0.000 description 1
238000010992 reflux Methods 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
210000005163 right hepatic lobe Anatomy 0.000 description 1
230000028327 secretion Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
201000011549 stomach cancer Diseases 0.000 description 1
GZCRRIHWUXGPOV-UHFFFAOYSA-N terbium atom Chemical compound [Tb] GZCRRIHWUXGPOV-UHFFFAOYSA-N 0.000 description 1
LMEHHJBYKPTNLM-UHFFFAOYSA-H terbium(3+);tricarbonate Chemical compound [Tb+3].[Tb+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O LMEHHJBYKPTNLM-UHFFFAOYSA-H 0.000 description 1
JGXYUFKDLOACSN-UHFFFAOYSA-N tert-butyl 2-[[2-[bis[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]amino]-3-(2-butoxyphenyl)propyl]-[2-[bis[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]amino]ethyl]amino]acetate Chemical compound CCCCOC1=CC=CC=C1CC(CN(CCN(CC(=O)OC(C)(C)C)CC(=O)OC(C)(C)C)CC(=O)OC(C)(C)C)N(CC(=O)OC(C)(C)C)CC(=O)OC(C)(C)C JGXYUFKDLOACSN-UHFFFAOYSA-N 0.000 description 1
BXOZHLBDWKSTJO-UHFFFAOYSA-N tert-butyl 2-[[2-[bis[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]amino]-3-(2-ethoxyphenyl)propyl]-[2-[bis[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]amino]ethyl]amino]acetate Chemical compound CCOC1=CC=CC=C1CC(CN(CCN(CC(=O)OC(C)(C)C)CC(=O)OC(C)(C)C)CC(=O)OC(C)(C)C)N(CC(=O)OC(C)(C)C)CC(=O)OC(C)(C)C BXOZHLBDWKSTJO-UHFFFAOYSA-N 0.000 description 1
229910003452 thorium oxide Inorganic materials 0.000 description 1
FRNOGLGSGLTDKL-UHFFFAOYSA-N thulium atom Chemical compound [Tm] FRNOGLGSGLTDKL-UHFFFAOYSA-N 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
238000012800 visualization Methods 0.000 description 1
229910052727 yttrium Inorganic materials 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations

Landscapes

Health & Medical Sciences (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Radiology & Medical Imaging (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

CZ971667A 1994-11-30 1995-11-20 Application of metal complexes as liver and gallbladder x-ray diagnostic agents CZ166797A3 (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US35108694A	1994-11-30	1994-11-30
US38740895A	1995-02-13	1995-02-13
US48056695A	1995-06-07	1995-06-07
PCT/DE1995/001644 WO1996016677A2 (fr)	1994-11-30	1995-11-20	Utilisation de complexes metalliques comme agents de radiodiagnostic du foie et de la vesicule biliaire en tomographie informatisee

Publications (1)

Publication Number	Publication Date
CZ166797A3 true CZ166797A3 (en)	1997-11-12

Family

ID=27407981

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CZ971667A CZ166797A3 (en)	1994-11-30	1995-11-20	Application of metal complexes as liver and gallbladder x-ray diagnostic agents

Country Status (13)

Country	Link
EP (1)	EP0794800A1 (fr)
JP (1)	JPH10509734A (fr)
CN (1)	CN1167443A (fr)
AU (1)	AU4173896A (fr)
CA (1)	CA2206558A1 (fr)
CZ (1)	CZ166797A3 (fr)
FI (1)	FI972285L (fr)
HU (1)	HUT77553A (fr)
IL (1)	IL116207A0 (fr)
NO (1)	NO972458D0 (fr)
PL (1)	PL320482A1 (fr)
SK (1)	SK68897A3 (fr)
WO (1)	WO1996016678A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69620582T2 (de) *	1995-01-26	2002-11-07	Nycomed Imaging As, Oslo	Verwendung von WISMUTVERBINDUNGEN zur Herstellung eines Arzneimittels zur Behandlung von Magenverstimmungen, die durch Helicobacter pylori verursacht werden
GB9501560D0 (en)	1995-01-26	1995-03-15	Nycomed Imaging As	Contrast agents
EP0885616A1 (fr) *	1997-06-20	1998-12-23	Schering Aktiengesellschaft	Utilisation d'agents de contraste à administration intraveneuse, et appareil pour la mammographie
US20130158241A1 (en) *	2010-06-11	2013-06-20	Bayer Intellectual Property Gmbh	Process for Preparing Crystalline 3,6,9-triaza-3,6,9-tris(carboxymethyl)-4-(4-ethoxybenzyl)undecanedioic Acid and Use for Production of Primovist®
JP2012254973A (ja) *	2011-05-18	2012-12-27	Sumitomo Chemical Co Ltd	脂肪族アミン配位セリウム錯体及び該錯体を含む素子
EP3107580B1 (fr) *	2014-02-18	2024-02-14	Medesis Pharma	Utilisation d'un système d'administration micellaire inverse de chélateurs de métaux et de radionucléides

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3922005A1 (de) *	1989-06-30	1991-01-10	Schering Ag	Derivatisierte dtpa-komplexe, diese verbindungen enthaltende pharmazeutische mittel, ihre verwendung und verfahren zu deren herstellung
DE4011684A1 (de) *	1990-04-06	1991-10-10	Schering Ag	Dtpa-monoamide, diese verbindungen enthaltende pharmazeutische mittel, ihre verwendung und verfahren zu deren herstellung
GB9122984D0 (en) *	1991-10-30	1991-12-18	Salutar Inc	Contrast media

1995
- 1995-11-20 EP EP95940207A patent/EP0794800A1/fr not_active Withdrawn
- 1995-11-20 FI FI972285A patent/FI972285L/fi unknown
- 1995-11-20 HU HU9800178A patent/HUT77553A/hu unknown
- 1995-11-20 CN CN95196523A patent/CN1167443A/zh active Pending
- 1995-11-20 WO PCT/EP1995/004547 patent/WO1996016678A1/fr not_active Application Discontinuation
- 1995-11-20 CA CA002206558A patent/CA2206558A1/fr not_active Abandoned
- 1995-11-20 JP JP8517855A patent/JPH10509734A/ja active Pending
- 1995-11-20 PL PL95320482A patent/PL320482A1/xx unknown
- 1995-11-20 CZ CZ971667A patent/CZ166797A3/cs unknown
- 1995-11-20 AU AU41738/96A patent/AU4173896A/en not_active Abandoned
- 1995-11-20 SK SK688-97A patent/SK68897A3/sk unknown
- 1995-11-30 IL IL11620795A patent/IL116207A0/xx unknown
1997
- 1997-05-29 NO NO972458A patent/NO972458D0/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
MX9703974A (es)	1997-09-30
WO1996016678A1 (fr)	1996-06-06
FI972285A0 (fi)	1997-05-29
NO972458L (no)	1997-05-29
PL320482A1 (en)	1997-09-29
FI972285A7 (fi)	1997-05-29
SK68897A3 (en)	1998-10-07
NO972458D0 (no)	1997-05-29
CN1167443A (zh)	1997-12-10
AU4173896A (en)	1996-06-19
CA2206558A1 (fr)	1996-06-06
HUT77553A (hu)	1998-05-28
IL116207A0 (en)	1996-01-31
EP0794800A1 (fr)	1997-09-17
JPH10509734A (ja)	1998-09-22
FI972285L (fi)	1997-05-29

Publication	Publication Date	Title
US5853699A (en)	1998-12-29	Use of tetra azacycle complexes as x-ray diagnostic agents for the liver and gallbladder
US5582814A (en)	1996-12-10	1-(p-n-butylbenzyl) DTPA for magnetic resonance imaging
US4916246A (en)	1990-04-10	Paramagnetic chelates useful for NMR imaging
US5236695A (en)	1993-08-17	MRI image enhancement of bone and related tissue using complexes of paramagnetic cations and polyphosphonate ligands
JP3007415B2 (ja)	2000-02-07	ホスホネート部分と非ホスホネート部分との両者を有するｍｒｉ用のポリアミノ常磁性キレート
CN110035996B (zh)	2022-08-09	用于磁共振成像的新型高弛豫性钆螯合物
JP2020500917A (ja)	2020-01-16	二量体造影剤
EP0513000B1 (fr)	1996-07-31	Ameloration d'images d'irm d'os et de tissus apparentes a l'aide de complexes de cations paramagnetiques et de ligands de polyphosphonate
CZ166797A3 (en)	1997-11-12	Application of metal complexes as liver and gallbladder x-ray diagnostic agents
JPH04225925A (ja)	1992-08-14	金属キレート造影剤用賦形剤
US5919431A (en)	1999-07-06	1,4,7,10-tetraazacyclododecane derivatives, their use, pharmaceutical agents containing these compounds and process for their production
MXPA97003974A (en)	1998-07-03	Use of metal complexs as x-ray diagnostic agents for the liver and the bil vesicula
CN108191695A (zh)	2018-06-22	一种用于ct的新型造影剂
JPH0656802A (ja)	1994-03-01	テトラアザシクロドデカン誘導体およびその用途
MXPA96004695A (en)	1999-01-11	Quelan compounds